3-D protein structure reveals a new mechanism for future anti-cancer drugs

Medical Xpress | February 15, 2019

3-D protein structure reveals a new mechanism for future anti-cancer drugs
A research team at the Medical University of South Carolina (MUSC) has discovered a new mechanism for a class of anti-cancer drugs known as E1 inhibitors. Their findings, published in Nature Communications on December 4, 2018, reveal a novel binding site that will promote drug design of more efficient E1 inhibitors. The team was led by Shaun Olsen, Ph.D., an assistant professor of Biology and Molecular Biology at MUSC and a member of the Developmental Cancer Therapeutics Program at Hollings Cancer Center. Olsen has dedicated his career to solving 3-D structures of proteins. Olsen and his team use these protein structures to model interactions with other molecules, including potential new drugs.
In the article, Olsen and his team report that they have discovered a new site on a protein, SUMO E1, which is a target for E1 inhibitors. The new binding site is located in the center of the protein and was previously thought to be out of reach. Olsen's team discovered an alternative conformation of the protein that exposes the site and allows a new inhibitor (COH000; Sumo Biosciences, Inc., Pasadena, CA) to bind.

Spotlight

Biotechnology and specifically Synthetic Biology (SynBio) is evolving at lightning speed. SynBio makes it possible to engineer life from the ground up (allowing the formation of organisms with genetic code (DNA) not found in the natural world) and to redesign existing natural bio systems for life-changing purposes.1 The opportunities are limitless and so are the risks.

Spotlight

Biotechnology and specifically Synthetic Biology (SynBio) is evolving at lightning speed. SynBio makes it possible to engineer life from the ground up (allowing the formation of organisms with genetic code (DNA) not found in the natural world) and to redesign existing natural bio systems for life-changing purposes.1 The opportunities are limitless and so are the risks.

Related News

European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation

Cellect Biotechnology | August 10, 2020

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034, subject to patent term adjustment or extension."This is a pivotal event for Cellect and perhaps one of the most crucial developments for us as we have secured IP protection over the second component of the Apograft™ effects – the activation of the stem and progenitor cells," commented Dr. Shai Yarkoni, Chief Executive Officer. "While the extensive issued patents cover the accurate elimination (negative selection) of the mature cells and therefor enables SAFETY, this patent covers the increased ACTIVITY (positive selection=efficacy) of the regenerative capacity of the stem and progenitor cells. Combined with our previously issued patents, our IP now cover the dual effects of the apoptotic proteins with a single, robust, and cost-effective process that is achieved outside of the patient's body. The clinical and economic benefits are multi-fold as we have demonstrated increased safety and efficacy of the cell product by developing a robust, non-expensive and user-friendly process and product.

Read More

K-cosmeceutical company Dermafirm USA, Inc. officially announced its U.S. expansion

PR Newswire | July 22, 2020

Today the K-cosmeceutical company Dermafirm USA, Inc., the U.S. arm of South Korea's Dermafirm Inc., is officially announcing its U.S. expansion. Plans are to formally introduce its U.S. leadership team on July 28th, at a private, virtual event. During the event, the company will kick off a movement with a mission to embrace scientific innovation, educate consumers on clean, natural and healthy DIY skincare options and ultimately empower users to perform these skincare regimens safely at home. Leadership will engage with attendees from the scientific, corporate and beauty industries to discuss and brainstorm on how this organic movement can best be evolved and deployed."It's in Dermafirm's DNA to innovate advanced skincare that is scientifically proven — and to go the extra step by helping to educate consumers on what to look for in products to help them make healthier choices," says Paula Park, Dermafirm USA's Founder and CEO. "And, by listening to consumers, we too are being educated — there are so many big promises in our industry — this is what inspired us to start this movement to change the way the world feels about skin care. We will be introducing a product line in late August that does exactly this — stay tuned."Listening to both customers' needs and current COVID-19 market demand led to the company's soon to be launched professional grade, prestige line pivot from B2B to D2C. Attendees of the upcoming event are currently sampling this line in order to share their experiences in real time with Dermafirm USA leadership. Then the discussion will continue focusing on sharing how the latest advances in biotechnology-based skincare formulations can be realized, packaged and presented directly to consumers as viable DIY regimens that are easily applied and get results.

Read More

MEDTECH

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effective when we enter the clinical evaluation stage,” said Jack O’Meara, CEO at Ochre Bio. “As we are progressing our preclinical evaluation, we are proud to support the great work of the British Liver Trust. We highly appreciate their effort in supporting patients, caregivers, and healthcare professionals on all aspects of liver health including prevention and early detection, and we look forward to a close partnership as we execute on our unified goal.” The British Liver Trust is the UK's leading liver health charity, recognised by Her Majesty's Revenue and Customs and the Charity Commissions in England, Wales and Scotland, is working to improve liver health and supporting patients affected by liver disease or cancer. Reaching millions of people each year, the British Liver Trust raises awareness for the risk factors of liver disease, provides advice to help people improving their liver health and submits the most updated information to patients. “In the UK, one out of six patients dies while waiting for a liver transplant. Ochre Bio’s research has the potential to improve these numbers and with that the chances of successful treatment for liver disease patients. We are really excited that Ochre Bio is supporting the aims of the British Liver Trust and we delighted to have this partnership with important shared goals,” Pamela Healy OBE, Chief Executive of the British Liver Trust About Ochre Bio Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. We uncover new biological pathways by using advances in 'deep phenotyping', and then study our medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines we bring to the clinic are highly likely to successfully improve patient lives. Situated within the heart of Oxford’s biotech innovation hub, Ochre is built on over 15 years experience in liver genomics and bringing advanced therapies to market.

Read More